Quantcast
Last updated on April 16, 2014 at 11:32 EDT

Latest Teriparatide Stories

2009-04-14 13:45:00

In-body stem cell therapy has enormous potential for bone injuries Rarely will physicians use the word "miraculous" when discussing patient recoveries. But that's the very phrase orthopedic physicians and scientists are using in upstate New York to describe their emerging stem cell research that could have a profound impact on the treatment of bone injuries. Results from preliminary work being released today show patients confined to wheelchairs were able to walk or live independently again...

2009-02-19 14:55:00

COLLEGEVILLE, Pa., Feb. 19 /PRNewswire-FirstCall/ -- The Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), today adopted a positive opinion recommending to grant a marketing authorization for CONBRIZA(TM) (bazedoxifene) for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. CONBRIZA, an investigational medicine, is in development by Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE)....

2009-01-06 10:32:00

BEDFORD, Mass., Jan. 6 /PRNewswire/ -- MicroCHIPS, Inc., a developer of intelligent implanted devices, has named Massachusetts General Hospital endocrinologist, Robert M. Neer, MD, to its Scientific Advisory Board. MicroCHIPS' has partnered with prominent clinicians to form a Scientific Advisory Board to support the company's innovative biosensing and drug delivery programs in diabetes, osteoporosis and other chronic diseases. As a leading physician and researcher in osteoporosis, Dr. Neer...

2008-10-27 12:00:29

Zosano Pharma, Inc., a privately held pharmaceutical company developing a novel transdermal delivery technology, today announced positive results from its phase 2, randomized, multi-center, double-blind, multi-dose study designed to determine safety and efficacy of its ZP-PTH rapid delivery patch for the treatment of osteoporosis. The product delivers PTH 1-34, teriparatide (PTH), a compound that has been proven to stimulate formation of new bone and reduce the risk of fractures. The ZP-PTH...

2008-10-20 06:00:22

Eli Lilly and Company has announced that its new Forteo delivery device is available for patient use in the US. The new delivery device was designed specifically for Forteo patients to help them more easily administer their treatment on a day-to-day basis, the company said. The new delivery device, approved by the FDA in June 2008, is being shipped to pharmacies and is available for patients when they fill their prescriptions in the coming weeks. The new Forteo delivery device includes a...

2008-10-15 09:00:08

INDIANAPOLIS, Oct. 15 /PRNewswire-FirstCall/ -- Eli Lilly and Company announced that its new, simpler-to-use FORTEO Delivery Device is available for patient use in the United States. The new delivery device was designed specifically for FORTEO(R) [teriparatide (rDNA origin) injection] patients to help them more easily administer their treatment on a day-to-day basis. The new delivery device, approved by the U.S. Food and Drug Administration (FDA) in June, is being shipped to pharmacies...

2008-09-15 18:00:11

The American College of Physicians (ACP) today released a new clinical practice guideline on drug treatment of osteoporosis or low bone density to prevent fracture in men and women. The guideline appears in the September 16, 2008, issue of Annals of Internal Medicine (www.annals.org). ACP recommends that physicians offer drug treatment to men and women who have been diagnosed with osteoporosis or a previous fracture not caused by substantial trauma. The guideline also recommends that...

2008-09-11 09:00:09

Zosano Pharma, Inc., a privately held pharmaceutical company developing a novel transdermal delivery technology, today announced that an abstract detailing results of its Phase 2 study of Zosano PTH Patch, a proprietary transdermal patch formulation of parathyroid hormone (PTH) for the treatment of established osteoporosis, has been accepted as a late-breaking poster presentation at the 2008 American College of Rheumatology Annual Scientific Meeting. In the study to be presented, treatment...

2008-07-25 12:01:20

Zelos Therapeutics has signed agreements with the FDA and the European Medicines Agency for a Phase III registration study of ZT-031 for the treatment of severe osteoporosis. Following the special clinical protocol assessment process with the FDA and a formal scientific advice meeting with the Committee for Human Medicinal Products of the European Medicines Agency (EMEA), Zelos Therapeutics has received regulatory approval for the design, conduct and analysis of a pivotal Phase III clinical...

2008-07-24 09:00:25

Zelos Therapeutics, Inc. has reached agreements with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) for a Phase 3 registration study of ZT-031 for the treatment of severe osteoporosis. Following the special clinical protocol assessment (SPA) process with the FDA and a formal scientific advice meeting with the Committee for Human Medicinal Products of the EMEA, Zelos Therapeutics has received regulatory approval for the design, conduct and analysis of a...